Cite
HARVARD Citation
Sborov, D. et al. (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & lymphoma. 58 (10), pp. 2310-2318. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sborov, D. et al. (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & lymphoma. 58 (10), pp. 2310-2318. [Online].